[1] Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015,373(17):1627-1639.
[2] Callahan M K, Horak C E, Curran M A, et al. Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab[J]. J Clin Oncol, 2013, 31(15): 2215-2218.
[3] Tumeh P C, Harview C L, Yearley J H, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance [J]. Nature, 2014, 515(7528): 568-571.
[4] Sun W Y, Lee Y K, Koo J S. Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies [J]. J Transl Med, 2016, 14(1):173.
[5] Ratcliffe M J, Sharpe A, Midha A, et al. Abstract LB-094: a comparative study of PD-L1 diagnostic assays and the classification of patients as PD-L1 positive and PD-L1 negative [J]. Cancer Res, 2016, 76(14 Suppl):LB-094.
[6] Stack E C, Foukas P G, Lee P P. Multiplexed tissue biomarker imaging[J]. J Immunother Cancer, 2016,4:9.
[7] Tokito T, Azuma K, Kawahara A, et al. Predictive relevance of PD-L1 expression combined with CD8⁺ TIL density in stage Ⅲ non-small cell lung cancer patients receiving concurrent chemoradiotherapy [J]. Eur J Cancer, 2016, 55: 7-14.
[8] Hamid O, Schmidt H, Nissan A, et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma [J]. J Transl Med, 2011, 9: 204.
[9] Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome [J]. Science, 2006, 313(5795):1960-1964.
[10] Taube J M, Klein A, Brahmer J R, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy[J]. Clin Cancer Res, 2014, 20(19):5064-5074.
[11] Ruggiero E, Nicolay J P, Fronza R, et al. High-resolution analysis of the human T-cell receptor repertoire [J]. Nat Commun, 2015, 6: 8081-8085.
[12] Groenen P J, Langerak A W, Van Dongen J J, et al. Pitfalls in TCR gene clonality testing: teaching cases [J]. J Hematop, 2008, 1(2): 97-109.
[13] Page D B, Yuan J, Redmond D, et al. Deep sequencing of T-cell receptor DNA as a biomarker of clonally expanded TILs in breast cancer after immunotherapy[J]. Cancer Immunol Res, 2016, 4(10):835-844.
[14] Postow M A, Manuel M, Wong P, et al. Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma [J]. J Immunother Cancer, 2015, 3(23): 70-75.
[15] Schumacher T N, Schreiber R D. Neoantigens in cancer immunotherapy [J]. Science, 2015, 348(6230): 69-74.
[16] Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma [J]. N Engl J Med, 2014, 371(23): 2189-2199.
[17] Rizvi N A, Hellmann M D, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer [J]. Science, 2015, 348(6230):124-128.
[18] Johnson D B, Frampton G M, Rioth M J, et al. Targeted next generation sequencing identifies markers of response to PD-1 blockade [J]. Cancer Immunol Res, 2016, 4(11): 959-967.
[19] Rosenberg J E, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial [J]. Lancet, 2016, 387(10031):1909-1920.
[20] Hugo W, Zaretsky J M, Sun L, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma [J]. Cell, 2016, 165(1): 35-44.
[21] Xiao Y, Freeman G J. The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy [J]. Cancer Discov, 2015, 5(1): 16-18.
[22] Eggink F A, Van Gool I C, Leary A, et al. Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition [J]. Oncoimmunology, 2017, 6(2): e1264565.
[23] Le D T, Uram J N, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency [J]. N Engl J Med, 2015, 372(26): 2509-2520.
[24] Mehnert J M, Panda A, Zhong H, et al. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer [J]. J Clin Invest, 2016, 126(6): 2334-2340.
[25] Ji R R, Chasalow S D, Wang L, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab [J]. Cancer Immunol Immunother, 2012, 61(7): 1019-1031.
[26] Johnson D B, Estrada M V, Salgado R, et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy [J]. Nat Commun, 2016, 7: 10582.
[27] Ribas A, Robert C, Hodi F S, et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature [J]. J Clin Oncol, 2015, 33(15_suppl): 3001.
[28] Ferrucci P F, Ascierto P A, Pigozzo J, et al. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab [J]. Ann Oncol, 2016, 27(4): 732-738.
[29] Delyon J, Mateus C, Lefeuvre D, et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival[J]. Ann Oncol, 2013,24(6):1697-1703.
[30] Weide B, Martens A, Hassel J C, et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab[J]. Clin Cancer Res, 2016, 22(22): 5487-5496.
[31] Zhang G, Xiang J, Xia Y, et al. PUB031 research on clinical effect and cytokines dynamic change of patient with advanced malignant tumor treated by PD-1 inhibitors [J]. J Thoracic Oncol, 2018, 12(11): S2375.
[32] Du W, Hu Y. P1.07-037 testing the positive and negative immune checkpoint on PBMCs of patients from initiatory to terminative treatment of anti PD-1 antibody [J]. J Thoracic Oncol, 2018, 12(11): S2010.